# A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)

> **NCT05939648** · PHASE2 · UNKNOWN · sponsor: **AIM Vaccine Co., Ltd.** · enrollment: 450 (actual)

## Conditions studied

- SARS-CoV-2

## Interventions

- **BIOLOGICAL:** SARS-CoV-2 Bivalent mRNA Vaccine
- **OTHER:** Saline

## Key facts

- **NCT ID:** NCT05939648
- **Lead sponsor:** AIM Vaccine Co., Ltd.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** UNKNOWN
- **Start date:** 2023-10-09
- **Primary completion:** 2023-11-30
- **Final completion:** 2024-12-30
- **Target enrollment:** 450 (ACTUAL)
- **Last updated:** 2023-11-24

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05939648

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05939648, "A Phase II Clinical Trial to Evaluate the Immunogenicity and Safety of SARS-CoV-2 Bivalent mRNA Vaccine (LVRNA021)". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT05939648. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*